Table 2.
Confirmation assays of plasma proteins in diabetes and their potential to discriminate lower limb sclerosis from controls (pg/ml).
| Proteins | protein array cohort† | confirmation cohort | ||
|---|---|---|---|---|
| CLI (n = 4) | Non-CLI (n = 4) | CLI (n = 59) | Non-CLI (n = 108) | |
| BMP-4 | 497.34 ± 26.24# | 385.74 ± 20.66 | 558.57 ± 34.20# | 437.14 (330.11–544.50)‡ |
| IGFBP-6 | 209.06 ± 21.49# | 99.93 ± 17.95 | 195.62 ± 19.59# | 124.14 (88.49–167.22)‡ |
| NCAM-1 | (182.92 ± 11.42)*10−3# | (277.58 ± 18.64)*10−3 | (264.20 ± 8.25)*10−3 | (264.40 ± 7.11)*10−3 |
| MSP-alpha | 57.34 ± 6.99# | 31.60 ± 3.14 | 59.30 ± 3.21 | 58.79 ± 2.13 |
| Siglec-5 | (258.76 ± 37.21)*103# | (45.66 ± 6.00)*103 | (193.62 (158.08–196.32))*103### | (73.84 ± 4.76)*103‡ |
| Axl | 14.64 ± 1.48# | 26.71 ± 1.64 | 23.33 ± 1.36 | 21.37 (13.74–29.02)‡ |
| Decorin | (1.90 ± 0.30)*103# | (3.52 ± 0.16)*103 | (3.75 ± 0.18)*103## | (3.14 ± 0.12)*103 |
| Trappin-2 | 33.42 ± 2.78# | 14.08 ± 2.49 | 23.22 (13.23–50.34)### | 13.22 (9.43–19.02)‡ |
| EpCAM | 10.23 ± 0.23# | 5.00 ± 1.25 | 7.30 ± 0.68 | 6.50 (1.38–10.88)‡ |
| TIMP-4 | (4.19 ± 0.30)*103# | (2.08 ± 0.21)*103 | (3.94 ± 0.41)*103### | (2.18 ± 0.22)*103 |
| CDH5 | (40.26 ± 1.77)*103# | (29.47 ± 1.59)*103 | (37.92 ± 1.23)*103### | (32.92 ± 0.56)*103 |
Data is shown as mean ± SEM, median (interquartile range) of subjects in each group. Differences between the groups in the protein array cohort were analyzed using †) Fisher-Pitman Permutation test, however, the confirmation cohort was analyzed using ‡) Mann-Whitney U-test, all the others were analyzed using t-tests. # p < 0.05; ## p < 0.01; ### p < 0.001.